JesÃ^os Rivera-Nieves

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6170118/publications.pdf

Version: 2024-02-01

566801 580395 1,294 27 15 25 citations g-index h-index papers 29 29 29 2234 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Antibody secreting cells are critically dependent on integrin $\hat{l}\pm4\hat{l}^27/MAdCAM-1$ for intestinal recruitment and control of the microbiota during chronic colitis. Mucosal Immunology, 2022, 15, 109-119.	2.7	15
2	Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis. Drugs, 2021, 81, 985-1002.	4.9	89
3	Vitamin D Levels May Predict Response to Vedolizumab. Journal of Crohn's and Colitis, 2021, 15, 1978-1979.	0.6	O
4	An integrin $\hat{l}\pm E\hat{l}^2$ 7-dependent mechanism of IgA transcytosis requires direct plasma cell contact with intestinal epithelium. Mucosal Immunology, 2021, 14, 1347-1357.	2.7	9
5	Microbial-Driven Immunological Memory and Its Potential Role in Microbiome Editing for the Prevention of Colorectal Cancer. Frontiers in Cellular and Infection Microbiology, 2021, 11, 752304.	1.8	2
6	Class Ib MHC–Mediated Immune Interactions Play a Critical Role in Maintaining Mucosal Homeostasis in the Mammalian Large Intestine. ImmunoHorizons, 2021, 5, 953-971.	0.8	0
7	Î ² 7 Integrin Inhibition Can Increase Intestinal Inflammation by Impairing Homing of CD25hiFoxP3+ Regulatory T Cells. Cellular and Molecular Gastroenterology and Hepatology, 2020, 9, 369-385.	2.3	22
8	Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn's-Like Ileitis by Suppressing Thymocyte Maturation. Inflammatory Bowel Diseases, 2020, 26, 216-228.	0.9	19
9	Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482097121.	1.4	7
10	Inherent Immune Cell Variation Within Colonic Segments Presents Challenges for Clinical Trial Design. Journal of Crohn's and Colitis, 2020, 14, 1364-1377.	0.6	7
11	Should We Divide Crohn's Disease Into lleum-Dominant and Isolated Colonic Diseases?. Clinical Gastroenterology and Hepatology, 2019, 17, 2634-2643.	2.4	85
12	Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. Frontiers in Pharmacology, 2019, 10, 212.	1.6	92
13	Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. Inflammatory Bowel Diseases, 2019, 25, 270-282.	0.9	48
14	Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis. Inflammatory Bowel Diseases, 2019, 25, 410-420.	0.9	28
15	Complex Network of NKT Cell Subsets Controls Immune Homeostasis in Liver and Gut. Frontiers in Immunology, 2018, 9, 2082.	2.2	35
16	Targeting leukocyte traffic: A new era for the treatment of Inflammatory bowel disease. Journal of Crohn's and Colitis, 2018, 12, S631-S632.	0.6	1
17	Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2366-2376.	0.9	6
18	Defective Lymphatics in Crohn's Disease: Tertiary Lymphoid Follicles Plug theÂGap. Gastroenterology, 2017, 152, 908-910.	0.6	2

#	Article	lF	CITATIONS
19	Ectopic Tertiary Lymphoid Tissue in Inflammatory Bowel Disease: Protective or Provocateur?. Frontiers in Immunology, 2016, 7, 308.	2.2	30
20	Opportunities for Improvement in the Care of Patients Hospitalized for Inflammatory Bowel Disease-Related Colitis. Digestive Diseases and Sciences, 2016, 61, 1003-1012.	1.1	17
21	Integrin-based therapeutics: biological basis, clinical use and new drugs. Nature Reviews Drug Discovery, 2016, 15, 173-183.	21.5	324
22	Innate Cytokines Dictate the Fate of Acute Intestinal Inflammation. Gastroenterology, 2015, 148, 248-250.	0.6	6
23	A Call for Investment in Education of US Minorities in the 21st Century. Gastroenterology, 2013, 144, 863-867.	0.6	10
24	Leukocyte Traffic Blockade as a Therapeutic Strategy in Inflammatory Bowel Disease. Current Drug Targets, 2013, 14, 1490-1500.	1.0	38
25	Strategies for the Care of Adults Hospitalized for Active Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2012, 10, 1315-1325.e4.	2.4	54
26	Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology, 2005, 128, 654-666.	0.6	150
27	Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology, 2001, 121, 1428-1436.	0.6	198